drugset
drugset / Trial / NCT04828343

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

NCT04828343 ↗

Phase 1 Completed 32 enrolled UCB Biopharma SRL
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to healthy participants by manual push (MP) versus (vs) syringe driver.

Timeline

Start
2021-04-22
Primary completion
2022-04-11
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rozanolixizumab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.